Announcements

  • Management of cytotoxic chemotherapy-induced hand-foot syndrome

    2020-05-14

    screenshot_529.jpg

    Improvements in systemic cancer treatments have resulted in more patients surviving for prolonged periods of time on treatment. This has made treatment-related toxicity and quality of life concerns increasingly relevant. Hand-foot syndrome (HFS) is a common skin reaction to systemic therapy that should be anticipated with chemotherapeutic treatments such as pegylated liposomal doxorubicin, docetaxel, and fluoropyrimidines. In this review we discuss current knowledge of the diagnosis, incidence, pathogenesis, and management of hand-foot syndrome (HFS). 

    Oncology Reviews https://doi.org/10.4081/oncol.2020.442

    Read more about Management of cytotoxic chemotherapy-induced hand-foot syndrome
  • Mitotic quiescence in hepatic cancer stem cells: An incognito mode

    2020-05-08

    screenshot_458.jpg

    https://doi.org/10.4081/oncol.2020.452

    Hepatocellular carcinoma represents one of the most aggressive cancers with high recurrence rates. The high recurrence is a major problem in the management of this disease. Cancer stem cells (CSCs) are often regarded as the basis of cancer recurrence. The anti-proliferative therapy kills the proliferating cells but induces mitotic quiescence in CSCs which remain as residual dormant CSCs. Later on, withdrawal of treatment reactivates the residual CSCs from dormancy to produce new cancer cells. The proliferation of these newly formed cancer cells initiates new tumor formation in the liver leading to tumor recurrence. HCC cells evade the immune surveillance via modulating the key immune cells by alpha feto-protein (AFP) secreted from CSCs or hepatic progenitor cells. This AFP mediated immune evasion assists in establishing new tumors by cancer cells in the liver.

    Read more about Mitotic quiescence in hepatic cancer stem cells: An incognito mode
  • Elucidating the pathogenic and biomarker potentials of FOXG1 in glioblastoma

    2020-05-08

    Glioblastoma (GB) is an extremely pugnacious brain cancer originating from neural stem (NS) cell-like cells. Forkhead box G1 (FOXG1; previously recognized as BF-1, qin, Chicken Brain Factor 1, or XBF-1 and renamed FOXG1 for mouse and human, and FoxG1 for other chordates) is an evolutionary preserved transcription factor driven from the forkhead box group of proteins FOXG1 modulates the speed of neurogenesis by maintaining progenitor cells in a proliferative mode as well as obstructing their differentiation into neurons during the initial periods of cortical formation. 

    Read more about Elucidating the pathogenic and biomarker potentials of FOXG1 in glioblastoma
  • COVID-19

    2020-03-11

    Dear Authors,
    a large number of reviewers in Europe and particularly in Italy, are clinicians: their commitment in the current public health emergency is aimed at helping and treating people. Our greatest thanks go to them.

    We renew our commitment to guarantee you the peer-review process of your papers submitted to the Journal as soon as possible and we are confident we have your understanding for possible small delays.

    The Editorial Board
    The Publisher

    Read more about COVID-19